| 3.1 0.53 (20.62%) | 03-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.87 |
1-year : | 4.52 |
| Resists | First : | 3.31 |
Second : | 3.87 |
| Pivot price | 2.85 |
|||
| Supports | First : | 2.74 |
Second : | 2.39 |
| MAs | MA(5) : | 2.66 |
MA(20) : | 2.9 |
| MA(100) : | 3.74  |
MA(250) : | 3.15 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 38.1 |
D(3) : | 18 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 6.26 | Low : | 0.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LIXT ] has closed below upper band by 17.2%. Bollinger Bands are 12.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.69 - 2.71 | 2.71 - 2.72 |
| Low: | 2.45 - 2.46 | 2.46 - 2.48 |
| Close: | 2.55 - 2.57 | 2.57 - 2.59 |
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
Tue, 10 Mar 2026
Lixte Biotechnology Enters Amended Share Exchange to Consolidate Liora Ownership With Orbit Capital - TradingView
Tue, 10 Mar 2026
LIXTE Biotechnology Holdings (LIXT) Adds Innovative LiGHT Therapy to Pipeline - Yahoo Finance
Mon, 02 Mar 2026
Improving the Odds: How LIXTE Biotechnology (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective - Digital Journal
Wed, 25 Feb 2026
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit - USA Today
Wed, 18 Feb 2026
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary - Yahoo Finance
Wed, 18 Feb 2026
LIXTE Biotechnology (LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 15.3 (%) |
| Shares Short | 99 (K) |
| Shares Short P.Month | 108 (K) |
| EPS | -1.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -68.4 % |
| Return on Equity (ttm) | -130.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -2.64 |
| PEG Ratio | 0 |
| Price to Book value | 7.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|